Evidence map›Paper›PMID 33153070›Full record

ArticleInternational journal of molecular sciences2020

Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6-7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A.

Stefano Guadagni, Antonietta Rosella Farina, Lucia Annamaria Cappabianca, Michela Sebastiano, Rita Maccarone, Veronica Zelli, Marco Clementi, Alessandro Chiominto, Gemma Bruera, Enrico Ricevuto and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Stefano GuadagniDepartment of Applied Clinical Sciences and Biotechnology, University of L'Aquila, 67100 L'Aquila, Italy.ORCID 0000-0001-8525-084X
Antonietta Rosella FarinaDepartment of Applied Clinical Sciences and Biotechnology, University of L'Aquila, 67100 L'Aquila, Italy.
Lucia Annamaria CappabiancaDepartment of Applied Clinical Sciences and Biotechnology, University of L'Aquila, 67100 L'Aquila, Italy.
Michela SebastianoDepartment of Applied Clinical Sciences and Biotechnology, University of L'Aquila, 67100 L'Aquila, Italy.
Rita MaccaroneDepartment of Applied Clinical Sciences and Biotechnology, University of L'Aquila, 67100 L'Aquila, Italy.ORCID 0000-0003-0648-3771
Veronica ZelliDepartment of Applied Clinical Sciences and Biotechnology, University of L'Aquila, 67100 L'Aquila, Italy.
Marco ClementiDepartment of Applied Clinical Sciences and Biotechnology, University of L'Aquila, 67100 L'Aquila, Italy.ORCID 0000-0002-9652-5148
Alessandro ChiomintoDepartment of Applied Clinical Sciences and Biotechnology, University of L'Aquila, 67100 L'Aquila, Italy.
Gemma BrueraDepartment of Applied Clinical Sciences and Biotechnology, University of L'Aquila, 67100 L'Aquila, Italy.ORCID 0000-0002-8407-2479
Enrico RicevutoDepartment of Applied Clinical Sciences and Biotechnology, University of L'Aquila, 67100 L'Aquila, Italy.
Giammaria FiorentiniDepartment of Onco-Hematology, Azienda Ospedaliera "Ospedali Riuniti Marche Nord", 61122 Pesaro, Italy.
Donatella SartiDepartment of Onco-Hematology, Azienda Ospedaliera "Ospedali Riuniti Marche Nord", 61122 Pesaro, Italy.
Andrew Reay MackayDepartment of Applied Clinical Sciences and Biotechnology, University of L'Aquila, 67100 L'Aquila, Italy.
University of L'Aquila · ITOspedali Riuniti Marche Nord · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Merkel cell carcinomas (MCCs) are rare, aggressive, cutaneous neuroendocrine tumours, approximately 80% of which are caused by the genomic integration of Merkel cell polyomavirus (MCPyV). MCPyV-positive MCCs carry poor prognosis in approximately 70% of cases, highlighting the need for greater understanding of the oncogenic mechanisms involved in pathogenesis, progression and post-therapeutic relapse, and translation into novel therapeutic strategies. In a previous pilot study, we reported a potential relationship between

Indexed as

Carcinoma, Merkel CellPolyomavirus InfectionsSkin NeoplasmsTumor Virus InfectionsAgedAged, 80 and overAlternative SplicingAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCell Transformation, NeoplasticCombined Modality TherapyDrug Administration RoutesFemaleHumansInterdisciplinary CommunicationItalyAntibodies, Monoclonal, HumanizedavelumabNTRK1 protein, humanReceptor, trkAentrectinibisolated pelvic and limb perfusionlarotrectinibMCPyV T-antigenMerkel cell carcinomaMerkel cell polyomavirustropomyosin tyrosine kinase receptorΔ exon 6–7 TrkAIII

Identifiers

PMID33153070
PMCPMC7662965
OpenAlexW3095878484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.